Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Share Price

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jun 01, 2023 2:44pm

183 Views

Post# 35475439

RE:RE:Share Price

CAR T

Thank you to the poster on STW., who posted the CAR T abstract. Very exciting; it appears they did not boost this time, and are advancing to clinical. The abstract seemed to have a very positive tone, but I just glanced at it. Input from those knowledgeable in this area welcomed, Please correct if I got it wrong.

A very confident abstract.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand